According to Calliditas Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.38406. At the end of 2023 the company had a P/S ratio of 4.40.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.40 | -25.89% |
2022 | 5.93 | -76.2% |
2021 | 24.9 | -99.71% |
2020 | > 1000 |